Published in J Virol on August 01, 1993
A human virus protein, poliovirus protein 2BC, induces membrane proliferation and blocks the exocytic pathway in the yeast Saccharomyces cerevisiae. EMBO J (1995) 1.69
Inefficient complementation activity of poliovirus 2C and 3D proteins for rescue of lethal mutations. J Virol (1995) 1.40
Poliovirus-encoded protease 2APro cleaves the TATA-binding protein but does not inhibit host cell RNA polymerase II transcription in vitro. J Virol (1997) 1.10
Replication of hepatitis A viruses with chimeric 5' nontranslated regions. J Virol (1996) 0.99
A stable HeLa cell line that inducibly expresses poliovirus 2A(pro): effects on cellular and viral gene expression. J Virol (2000) 0.98
A poliovirus 2A(pro) mutant unable to cleave 3CD shows inefficient viral protein synthesis and transactivation defects. J Virol (1995) 0.98
Hepatitis A viruses with deletions in the 2A gene are infectious in cultured cells and marmosets. J Virol (1995) 0.91
Theiler's virus as a vector for foreign gene delivery. J Virol (1995) 0.84
Encapsidation and serial passage of a poliovirus replicon which expresses an inactive 2A proteinase. J Virol (1995) 0.83
Identification of LTR-specific small non-coding RNA in FeLV infected cells. FEBS Lett (2009) 0.80
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science (1988) 220.77
Production of single-stranded plasmid DNA. Methods Enzymol (1987) 39.38
Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature (1988) 19.07
Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature (1981) 16.61
Cloned poliovirus complementary DNA is infectious in mammalian cells. Science (1981) 12.50
ompT encodes the Escherichia coli outer membrane protease that cleaves T7 RNA polymerase during purification. J Bacteriol (1988) 6.64
A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell (1986) 5.53
Systematic nomenclature of picornavirus proteins. J Virol (1984) 5.26
Cap-independent translation of poliovirus mRNA is conferred by sequence elements within the 5' noncoding region. Mol Cell Biol (1988) 4.97
Poliovirus mutant that does not selectively inhibit host cell protein synthesis. Mol Cell Biol (1985) 4.94
Poliovirus proteinase 2A induces cleavage of eucaryotic initiation factor 4F polypeptide p220. J Virol (1987) 4.52
Production of infectious poliovirus from cloned cDNA is dramatically increased by SV40 transcription and replication signals. Nucleic Acids Res (1984) 4.19
Regulation of translation by poliovirus. Adv Virus Res (1987) 4.08
Genetic complementation among poliovirus mutants derived from an infectious cDNA clone. J Virol (1986) 3.65
Proteolytic processing of picornaviral polyprotein. Annu Rev Microbiol (1990) 3.40
Poliovirus polypeptide precursors: expression in vitro and processing by exogenous 3C and 2A proteinases. Proc Natl Acad Sci U S A (1987) 2.98
Poliovirus protein 3CD is the active protease for processing of the precursor protein P1 in vitro. J Gen Virol (1988) 2.71
Construction and characterization of poliovirus subgenomic replicons. J Virol (1988) 2.69
Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon. Virology (1991) 2.63
Translation in mammalian cells of a gene linked to the poliovirus 5' noncoding region. Science (1988) 2.53
Relationship of p220 cleavage during picornavirus infection to 2A proteinase sequencing. J Virol (1988) 2.32
In vitro construction of poliovirus defective interfering particles. J Virol (1989) 2.10
The cellular 68,000-Mr protein kinase is highly autophosphorylated and activated yet significantly degraded during poliovirus infection: implications for translational regulation. J Virol (1989) 1.96
Replication of poliovirus RNA and subgenomic RNA transcripts in transfected cells. J Virol (1992) 1.88
Molecular characterization of an attenuated human immunodeficiency virus type 2 isolate. J Virol (1990) 1.86
Poliovirus-induced inhibition of host-cell protein synthesis. Cell (1982) 1.79
Inhibition of translation in cells infected with a poliovirus 2Apro mutant correlates with phosphorylation of the alpha subunit of eucaryotic initiation factor 2. J Virol (1989) 1.77
The host protein required for in vitro replication of poliovirus is a protein kinase that phosphorylates eukaryotic initiation factor-2. Cell (1985) 1.64
Processing determinants required for in vitro cleavage of the poliovirus P1 precursor to capsid proteins. J Virol (1987) 1.61
Identification of essential amino acid residues in the functional activity of poliovirus 2A protease. Virology (1991) 1.61
Expression of human immunodeficiency virus type 1 (HIV-1) gag, pol, and env proteins from chimeric HIV-1-poliovirus minireplicons. J Virol (1991) 1.46
trans rescue of a mutant poliovirus RNA polymerase function. J Virol (1991) 1.35
Coinfection with recombinant vaccinia viruses expressing poliovirus P1 and P3 proteins results in polyprotein processing and formation of empty capsid structures. J Virol (1991) 1.26
Characterization of the roles of conserved cysteine and histidine residues in poliovirus 2A protease. Virology (1992) 1.19
Alternate poliovirus nonstructural protein processing cascades generated by primary sites of 3C proteinase cleavage. Virology (1992) 1.17
Mechanism of selective translation of vaccinia virus mRNAs: differential role of poly(A) and initiation factors in the translation of viral and cellular mRNAs. J Virol (1991) 1.08
Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J Virol (1991) 2.65
Construction of a type 1 human immunodeficiency virus that maintains a primer binding site complementary to tRNA(His). J Virol (1996) 2.30
The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles. J Virol (1992) 2.17
Human immunodeficiency virus type 1 can use different tRNAs as primers for reverse transcription but selectively maintains a primer binding site complementary to tRNA(3Lys). J Virol (1995) 2.16
Deletions in the tRNA(Lys) primer-binding site of human immunodeficiency virus type 1 identify essential regions for reverse transcription. J Virol (1991) 1.97
Identification of a novel retroviral gene unique to human immunodeficiency virus type 2 and simian immunodeficiency virus SIVMAC. J Virol (1988) 1.66
The host protein required for in vitro replication of poliovirus is a protein kinase that phosphorylates eukaryotic initiation factor-2. Cell (1985) 1.64
Identification of a sequence within U5 required for human immunodeficiency virus type 1 to stably maintain a primer binding site complementary to tRNA(Met). J Virol (1997) 1.60
Minimal sequence requirements of a functional human immunodeficiency virus type 1 primer binding site. J Virol (1994) 1.56
Enzymatic activity of poliovirus RNA polymerase mutants with single amino acid changes in the conserved YGDD amino acid motif. J Virol (1991) 1.49
ATP is required for initiation of poliovirus RNA synthesis in vitro: demonstration of tyrosine-phosphate linkage between in vitro-synthesized RNA and genome-linked protein. J Virol (1984) 1.47
Expression of human immunodeficiency virus type 1 (HIV-1) gag, pol, and env proteins from chimeric HIV-1-poliovirus minireplicons. J Virol (1991) 1.46
Cytokine production in motor neurons by poliovirus replicon vector gene delivery. Nat Biotechnol (2000) 1.44
Mutations in both the U5 region and the primer-binding site influence the selection of the tRNA used for the initiation of HIV-1 reverse transcription. Virology (1996) 1.34
Encapsidation of genetically engineered poliovirus minireplicons which express human immunodeficiency virus type 1 Gag and Pol proteins upon infection. J Virol (1993) 1.32
Mutation of the aspartic acid residues of the GDD sequence motif of poliovirus RNA-dependent RNA polymerase results in enzymes with altered metal ion requirements for activity. J Virol (1995) 1.27
Coinfection with recombinant vaccinia viruses expressing poliovirus P1 and P3 proteins results in polyprotein processing and formation of empty capsid structures. J Virol (1991) 1.26
Myristylation of poliovirus capsid precursor P1 is required for assembly of subviral particles. J Virol (1992) 1.25
Expression of enzymatically active poliovirus RNA-dependent RNA polymerase in Escherichia coli. Proc Natl Acad Sci U S A (1987) 1.24
Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles. Virology (1993) 1.22
Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1. J Virol (1996) 1.18
Antibody to poliovirus genome-linked protein (VPg) precipitates in vitro synthesized RNA attached to VPg-precursor polypeptide(s). Virus Res (1984) 1.15
Complementation of a poliovirus defective genome by a recombinant vaccinia virus which provides poliovirus P1 capsid precursor in trans. J Virol (1993) 1.15
Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogs. Antimicrob Agents Chemother (1994) 1.12
Human immunodeficiency virus type-1 reverse transcriptase. Contribution of Met-184 to binding of nucleoside 5'-triphosphate. J Biol Chem (1996) 1.12
Nucleotide substitutions within U5 are critical for efficient reverse transcription of human immunodeficiency virus type 1 with a primer binding site complementary to tRNA(His). J Virol (1997) 1.11
Identification of a human immunodeficiency virus type 1 that stably uses tRNALys1,2 rather than tRNALys,3 for initiation of reverse transcription. Virology (1999) 1.07
Essential regions of the tRNA primer required for HIV-1 infectivity. Nucleic Acids Res (2000) 1.04
Characterization of poliovirus replicons encoding carcinoembryonic antigen. Cancer Res (1994) 1.03
Amino acid substitutions in the poliovirus maturation cleavage site affect assembly and result in accumulation of provirions. J Virol (1995) 1.02
The RNA encompassing the internal ribosome entry site in the poliovirus 5' nontranslated region enhances the encapsidation of genomic RNA. Virology (2000) 1.00
Mutations within the primer binding site of the human immunodeficiency virus type 1 define sequence requirements essential for reverse transcription. Virology (1996) 0.99
Demonstration of the specificity of poliovirus encapsidation using a novel replicon which encodes enzymatically active firefly luciferase. Virology (1998) 0.96
Genetic evidence of the interaction between tRNA(Lys,3) and U5 facilitating efficient initiation of reverse transcription by human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1998) 0.93
Purification of a soluble template-dependent rhinovirus RNA polymerase and its dependence on a host cell protein for viral RNA synthesis. J Virol (1985) 0.93
Analysis of human anti-diphtheria antibodies by isoelectric focusing: evidence for restricted clonal heterogeneity of anti-fragment A antibodies. Infect Immun (1981) 0.93
Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag. J Virol (1996) 0.91
Multiple subsets of anti-tetanus toxoid antibody-producing cells in human peripheral blood differ by size, expression of membrane receptors, and mitogen reactivity. J Immunol (1981) 0.91
Poliovirus replicons that express the gag or the envelope surface protein of simian immunodeficiency virus SIV(smm) PBj14. Virology (1996) 0.89
Complementarity between 3' terminal nucleotides of tRNA and primer binding site is a major determinant for selection of the tRNA primer used for initiation of HIV-1 reverse transcription. Virology (1999) 0.89
Identification of critical elements in the tRNA acceptor stem and T(Psi)C loop necessary for human immunodeficiency virus type 1 infectivity. J Virol (2001) 0.88
Stability of HIV type 1 proviral genomes that contain two distinct primer-binding sites. AIDS Res Hum Retroviruses (1997) 0.87
Poliovirus replicons encoding the B subunit of Helicobacter pylori urease elicit a Th1 associated immune response. Vaccine (1999) 0.86
Mutations in the poliovirus P1 capsid precursor at arginine residues VP4-ARG34, VP3-ARG223, and VP1-ARG129 affect virus assembly and encapsidation of genomic RNA. Virology (1994) 0.86
Insights into the interaction between tRNA and primer binding site from characterization of a unique HIV-1 virus which stably maintains dual PBS complementary to tRNA(Gly) and tRNA(His). Virology (1997) 0.85
Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins. AIDS Res Hum Retroviruses (1997) 0.84
Preferential completion of human immunodeficiency virus type 1 proviruses initiated with tRNA3Lys rather than tRNA1,2Lys. J Virol (1998) 0.84
Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins. Vaccine (1995) 0.84
Primer-dependent eukaryotic RNA polymerase capable of accurate transcription from the adenovirus major late promoter in a reconstituted system. Proc Natl Acad Sci U S A (1985) 0.83
Expression of poliovirus P3 proteins using a recombinant vaccinia virus results in proteolytically active 3CD precursor protein without further processing to 3Cpro and 3Dpol. Virus Res (1993) 0.83
Encapsidation and serial passage of a poliovirus replicon which expresses an inactive 2A proteinase. J Virol (1995) 0.83
Inherent instability of poliovirus genomes containing two internal ribosome entry site (IRES) elements supports a role for the IRES in encapsidation. J Virol (2000) 0.83
Poliovirus assembly and encapsidation of genomic RNA. Adv Virus Res (1996) 0.82
Immunization of mice with poliovirus replicons expressing the C-fragment of tetanus toxin protects against lethal challenge with tetanus toxin. Vaccine (1997) 0.82
Poliovirus capsid proteins derived from P1 precursors with glutamine-valine cleavage sites have defects in assembly and RNA encapsidation. J Virol (1993) 0.81
Construction and characterization of encapsidated poliovirus replicons that express biologically active murine interleukin-2. J Interferon Cytokine Res (1998) 0.80
RNA replicons derived from poliovirus are directly oncolytic for human tumor cells of diverse origins. Cancer Res (2001) 0.79
Inhibition of Leishmania donovani amastigote-to-promastigote transformation by infected hamster spleen lymphocyte lysates. J Protozool (1980) 0.79
Repetitive intrathecal injections of poliovirus replicons result in gene expression in neurons of the central nervous system without pathogenesis. Hum Gene Ther (2001) 0.78
Targeted foreign gene expression in spinal cord neurons using poliovirus replicons. J Neurovirol (2000) 0.76
An aspartic acid at amino acid 108 is required to rescue infectious virus after transfection of a poliovirus cDNA containing a CGDD but not SGDD amino acid motif in 3Dpol. J Virol (1995) 0.75
Human IgA antibody and immunoglobulin production after in vivo tetanus toxoid immunization: size and surface membrane phenotype analysis. J Clin Immunol (1982) 0.75